JP2010501604A - グルコースレベルを低下させる方法 - Google Patents

グルコースレベルを低下させる方法 Download PDF

Info

Publication number
JP2010501604A
JP2010501604A JP2009525948A JP2009525948A JP2010501604A JP 2010501604 A JP2010501604 A JP 2010501604A JP 2009525948 A JP2009525948 A JP 2009525948A JP 2009525948 A JP2009525948 A JP 2009525948A JP 2010501604 A JP2010501604 A JP 2010501604A
Authority
JP
Japan
Prior art keywords
ramipril
patient
glucose
level
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009525948A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010501604A5 (enExample
Inventor
ハーツェル・ガースタイン
サリム・ユースフ
Original Assignee
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング filed Critical サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Publication of JP2010501604A publication Critical patent/JP2010501604A/ja
Publication of JP2010501604A5 publication Critical patent/JP2010501604A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
JP2009525948A 2006-08-28 2007-08-14 グルコースレベルを低下させる方法 Pending JP2010501604A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84085006P 2006-08-28 2006-08-28
PCT/EP2007/007160 WO2008025450A1 (en) 2006-08-28 2007-08-14 Methods of lowering glucose levels

Publications (2)

Publication Number Publication Date
JP2010501604A true JP2010501604A (ja) 2010-01-21
JP2010501604A5 JP2010501604A5 (enExample) 2010-09-24

Family

ID=38578487

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009525948A Pending JP2010501604A (ja) 2006-08-28 2007-08-14 グルコースレベルを低下させる方法

Country Status (12)

Country Link
US (1) US20080188538A1 (enExample)
EP (1) EP2059242A1 (enExample)
JP (1) JP2010501604A (enExample)
KR (1) KR20090042976A (enExample)
CN (1) CN101573110A (enExample)
AU (1) AU2007291602B2 (enExample)
BR (1) BRPI0716411A2 (enExample)
CA (1) CA2661598A1 (enExample)
IL (1) IL197189A0 (enExample)
MX (1) MX2009002091A (enExample)
NO (1) NO20090926L (enExample)
WO (1) WO2008025450A1 (enExample)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003527325A (ja) * 1999-08-30 2003-09-16 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 心血管の病態の予防におけるレニン−アンギオテンシン系阻害剤の使用
JP2005531492A (ja) * 2001-10-17 2005-10-20 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 高リスク患者のｉｉ型糖尿病を低減させる方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA817261B (en) * 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
DE3226768A1 (de) * 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
DE3413710A1 (de) * 1984-04-12 1985-10-24 Hoechst Ag, 6230 Frankfurt Verfahren zur behandlung der herzinsuffizienz
DE3739690A1 (de) * 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
CA2026686A1 (en) * 1989-10-30 1991-05-01 Werner Tschollar Method for preventing onset of type ii diabetes employing an ace inhibitor
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
US20050065203A1 (en) * 2001-10-17 2005-03-24 Salim Yusuf Method of reducing type 2 diabetes in high risk patients
WO2004080482A2 (en) * 2003-03-11 2004-09-23 Institut De Cardiologie De Montréal / Use of angiotensin converting enzyme (ace) inhibitors to prevent diabetes in a subject with chronic heart failure

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003527325A (ja) * 1999-08-30 2003-09-16 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 心血管の病態の予防におけるレニン−アンギオテンシン系阻害剤の使用
JP2005531492A (ja) * 2001-10-17 2005-10-20 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 高リスク患者のｉｉ型糖尿病を低減させる方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012058351; Ｔｈｅ　ＤＲＥＡＭ　Ｔｒｉａｌ　Ｉｎｖｅｓｔｉｇａｔｏｒｓ: Ｄｉａｂｅｔｏｌｏｇｉａ Ｖｏｌ．４７, 2004, ｐ．１５１９-１５２７ *

Also Published As

Publication number Publication date
AU2007291602A1 (en) 2008-03-06
MX2009002091A (es) 2009-03-09
IL197189A0 (en) 2009-12-24
NO20090926L (no) 2009-03-27
KR20090042976A (ko) 2009-05-04
CA2661598A1 (en) 2008-03-06
WO2008025450A1 (en) 2008-03-06
BRPI0716411A2 (pt) 2013-09-24
EP2059242A1 (en) 2009-05-20
US20080188538A1 (en) 2008-08-07
AU2007291602B2 (en) 2012-09-06
CN101573110A (zh) 2009-11-04

Similar Documents

Publication Publication Date Title
Scott et al. Esomeprazole: a review of its use in the management of acid-related disorders
JP4466370B2 (ja) 過活動膀胱治療剤
KR20070085754A (ko) 안정화된 라미프릴 조성물 및 제조 방법
EP3626270A1 (en) New use
MD3684344T2 (ro) Comprimate de deferipronă cu eliberare întârziată și metode de utilizare a acestora
CN108012527A (zh) 苯并咪唑衍生物用于夜间酸突破的用途
WO2010009618A1 (zh) 用于治疗高血压和代谢综合症的药物组合物及其应用
JP6499634B2 (ja) 過活動膀胱の治療のためのソリフェナシンと唾液分泌刺激剤の組合せ
US20050203124A1 (en) Compounds for the sustained reduction of body weight
JPWO2004002473A1 (ja) 血糖コントロール用医薬組成物
US10258617B2 (en) Dosing regimens for fast onset of antidepressant effect
TWI867128B (zh) 前列腺環素衍生物用於製造用以抑制轉入透析或腎死之藥劑之用途
AU2016301689B2 (en) Ameliorating agent for detrusor hyperactivity with impaired contractility
JP2010501604A (ja) グルコースレベルを低下させる方法
JP2015522612A (ja) 急性冠症候群の治療におけるニコチンアミド誘導体
JP2008189679A (ja) ２型糖尿病治療用の併用医薬
Çetin Fixed-dose combination-orally disintegrating tablet (FDC-ODT) studies for the treatment of type 2 diabetes or cardiovascular diseases-a mini review
KR100709531B1 (ko) 당뇨병성 합병증의 예방 또는 진전저지용 의약조성물
HK1138182A (en) Methods of lowering glucose levels
US20250367137A1 (en) Phloroglucinol Formulations And Methods Of Use
US20250375406A1 (en) Treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
JP2019510777A (ja) Ｎｓａｉｄ誘発性の心血管、脳血管又は腎血管の有害事象を治療するための方法
WO2025038481A1 (en) Vepdegestrant dosage regimen in cyp3a-inducer treatment in cancer
TW201103544A (en) Pharmaceutical composition and application thereof
HK40025703A (en) Mpges-1 inhibitor for the treatment of osteoarthritis pain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100804

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130521